Towards Implementation of Pharmacogenomics-guided Therapy in Patients with Mental Illness - Stage 2 & Stage 3 (ENACT)

Not Applicable

Recruiting

• Conditions: Major Depressive Disorder; Anxiety Disorders; Mental Health - Depression; Mental Health - Anxiety

• Registration Number: ACTRN12621001368820
• Lead Sponsor: St Vincent's Health Australia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-10-11
• Last Update Posted: 1 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1.Aged between 16 years and 70 years inclusive
2.Have a diagnosis of a Major Depressive Disorder (MDD) and/or Anxiety Disorder requiring psychotropic medications (either antidepressants or antipsychotics, or both) as part of their standard care
3.Are either new to psychotropic medication treatment or had psychotropic medication changes in the last three months
4.Sufficiently fluent in English
5.Have both mental and intellectual capacity to provide written or verbal informed consent
6.Willingness to participate in study and complete survey questions
7.Willingness to undergo PG genetic testing
8.Willingness to consider PG-guided psychotropic medication treatment prescribed by treating psychiatrist

Participants with a stable psychotic disorder as a psychiatric comorbidity will not be excluded.
Participants who are receiving other treatment, such as electroconvulsive therapy (ECT) and/or other medications, will not be excluded.

Exclusion Criteria

1.Significant suicidal risk
2.Mental, cognitive or intellectual impairment interfering with capacity to consent
3.Unwilling to comply with study schedule and requirements

Study & Design

• Study Type: Interventional
• Study Design: Not specified